파미셀

Business Overview

Pamiesel is a biopharmaceutical company specializing in the development of the world's first stem cell therapy, 'Hearticellgram-AMI,' with two business divisions: the Biomedical division, which provides stem cell therapies, skincare products, and adult stem cell preservation services, and the Biochemical division, which produces pharmaceutical intermediates, electronic materials, and eco-friendly flame retardants. In 2022, total sales reached 64.85 billion won, with the Biochemical division contributing 62.78 billion won, primarily driven by precision chemical product sales.